More than half of all drug overdose deaths in the United States now involve stimulants such as methamphetamine and cocaine. There are no approved medications to treat stimulant addiction. Yet a psychologist-developed intervention has been quietly delivering results for decades. It is called contingency management. The evidence behind it is hard to ignore.

So why are so few people still able to access it?

What Is Contingency Management?

At its core, contingency management is a structured approach to behaviour change. It is rooted in operant conditioning, the same psychological theory that underpins everyday ideas about rewards and consequences. In practice, it works like this: a person attending treatment provides an objective measure of abstinence, usually a urine sample. If the result is negative, they receive a tangible reward. That might be a gift card, a small cash incentive, or points redeemable for goods.

“Contingency management is really just thinking about that in the addiction space,” explains Dr Lara Coughlin, a licensed clinical psychologist and associate professor at the University of Michigan Addiction Centre. “It is counterbalancing the powerful reinforcing effects of drug use by making recovery-oriented behaviours immediately rewarding. And that ‘immediately’ part is really important.”

The immediacy is central to how the intervention works. Telling someone they might receive a financial benefit in a year’s time does little to change behaviour. But the promise of ten dollars today, right now, after a clean test, can be enough to tip the scales.

Dr Michael McDonell, professor at Washington State University’s Elson S Floyd College of Medicine, points to a striking series of studies. In one trial from the 1990s, researchers placed a line of cocaine in front of people who regularly used the drug. They were offered a choice: take the cocaine, or receive a small cash sum. When the amount was just five cents, around 80 per cent chose the cocaine. Once the cash rose to two dollars, roughly 80 per cent chose the money instead.

“When you’re a person who has a substance use disorder,” says Dr McDonell, “sometimes that drug becomes your only reward. When we offer a small tangible opportunity to pick something else, most people will choose that non-drug incentive.”

How Motivational Incentives Work: The Psychology Behind It

The brain’s reward system is powerful. Addiction effectively hijacks it. What contingency management does is introduce a competing, immediate reward into that system. There is no lecturing, no punishment. The approach simply makes one choice slightly more attractive than the other, right now, in this moment.

This is also why the size of the reward matters less than it might seem. It is not about the money itself. It is about immediacy and recognition. A ten-dollar gift card received within minutes of a negative test carries a different psychological weight to a promise of a larger sum later.

The Evidence Is Substantial

Contingency management is not experimental. Decades of randomised controlled trials have shown it works. And not only for stimulants. Research shows that motivational incentives meaningfully support people attempting to quit smoking, reduce alcohol use, and stay on course with opioid use disorder treatment alongside medications such as buprenorphine.

People in contingency management programmes for smoking are more than twice as likely to successfully quit. This holds even when combined with nicotine replacement therapies and approved medications. Tobacco remains the largest preventable cause of death and disease in the United States. That figure matters.

The mortality data is equally striking. Research in the Veterans Health Administration used a three-month contingency management model. It found that people with stimulant use disorder who received the intervention were around 40 per cent less likely to die over the following year. The reduction in overdose deaths and all-cause mortality is comparable in scale to medication-assisted treatment for opioid use disorder.

“We have a lifesaving solution,” says Dr Coughlin. “It is our job as a field and as providers to make sure this is available widely.”

Not a Punishment System

One persistent misconception about motivational incentives is that they create a punitive dynamic. A positive test result, in this model, does not bring shame or consequences. The reality is the opposite.

Rather than using urine testing to catch people out, contingency management uses it as a gateway to reward. When a test comes back positive, there is no reprimand. Participants are encouraged to try again.

“We flip the script on urine testing,” says Dr McDonell. “People often have a shocked look on their face when we say, ‘Your result’s positive, keep trying, come back in a couple of days.’ They’re like, ‘You’re not going to call my probation officer?’ We say, ‘No, come back again, try again.'”

That repeated opportunity for success, offered twice weekly, is built into the model. The frequency matters. If someone does not manage abstinence one day, they can try again in two days. Research shows that the momentum of early success builds over time. Reengaging with family, employment, and daily stability starts to provide its own rewards.

The idea that people simply return to drug use once incentives stop is not supported by the data. Studies show that contingency management produces better long-term outcomes than other stimulant use interventions, even after the programme ends.

Who Does Contingency Management Work For?

Socioeconomic status does not appear to predict whether someone responds to contingency management. A gift card worth ten or twenty pounds does not need to represent major purchasing power. For many people, its value lies in what it signals: recognition, positive reinforcement, and trust.

“There’s no evidence that your socioeconomic status predicts whether or not you respond to contingency management,” says Dr McDonell. “It may be more related to your decision-making process and the way you see costs versus benefits of any particular decision.”

What does affect response rates is the severity of the addiction itself. More severe substance use disorders show lower response rates across all treatments, not just this one. Researchers are working to understand which personalised approaches might better support people at different stages.

Digital Delivery and Remote Contingency Management

Traditionally, contingency management programmes require participants to attend a clinic twice a week. For people in rural areas, those with childcare responsibilities, or those without reliable transport, this is a real barrier. Research is now exploring virtual delivery, with encouraging results.

One approach uses a home breathalyser for alcohol use disorder. The participant blows into the device and takes a selfie. Facial recognition software confirms their identity. If the result is negative, an incentive arrives automatically via text. Another model uses a blood-based biomarker that participants self-collect and post to a laboratory. A confirmed negative triggers a digital reward.

In one ongoing virtual study on alcohol use disorder, three quarters of participants had never previously received any treatment for their drinking. Removing the clinic visit appears to be a meaningful factor in reaching people who might otherwise never engage with services at all.

Digital motivational incentive programmes also open doors in smoking cessation. Participants monitor their own carbon monoxide levels using a handheld device and receive rewards through an app.

“There is definitely a space for digital contingency management,” says Dr Coughlin. “We need to be thinking about how that interfaces with what is really important to us as humans, which is connecting with someone and that sense of belonging.”

Growing Momentum, Persistent Barriers

The Veterans Health Administration has been delivering contingency management across more than 100 facilities since 2011. A small number of US states have since begun rolling out programmes, often for Medicaid beneficiaries with stimulant use disorder.

California and Washington State have secured Medicaid demonstration waivers. These allow contingency management to be delivered in community treatment settings. Michigan is using opioid settlement funds to run a comparable programme. Vermont and Maine are among others following suit.

At a federal level, the Substance Abuse and Mental Health Services Administration raised its incentive cap from 75 to 750 dollars per patient per year. This aligns more closely with what research suggests is an effective dose across a three to six month course.

Why Funding and Regulation Still Block Access

Yet the intervention remains out of reach for most people who could benefit.

There is no billing code for contingency management. This makes it hard for providers to seek reimbursement through standard healthcare channels. The Veterans Health Administration’s success is partly a product of its structurally different funding model. Most community providers cannot replicate it.

Regulatory concerns add further complexity. Federal rules have historically restricted the offering of incentives to Medicaid patients, following widespread fraud in other healthcare settings unrelated to addiction. Obtaining regulatory approvals remains daunting for many providers.

“People do not want to be subject to a Medicaid fraud investigation,” says Dr McDonell. “We know contingency management is not fraud, waste and abuse. The federal government has been very clear on that, but feeling comfortable and willing to implement it is another thing.”

There is also the barrier of public perception. Headlines asking why anyone is “paying people to stop using drugs” have created stigma around an intervention grounded in well-established psychological science.

A Treatment Whose Time Has Come

Despite the obstacles, things are shifting. Payers, insurers, and state governments are paying closer attention. Researchers are training a new generation of contingency management champions within clinics, health departments, and federal agencies. Digital platforms are making the approach more scalable than ever before.

For people living with stimulant use disorder, where no medication exists and evidence for other therapies remains limited, motivational incentives are one of the most powerful tools available. For those working to address alcohol use disorder and smoking, the same principles apply.

The science has been there for decades. The work now is getting it to the people who need it.

Source: dbrecoveryresources